Sei Investments Co. Buys 31,055 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Sei Investments Co. grew its stake in shares of Royalty Pharma plc (NASDAQ:RPRX) by 81.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 69,071 shares of the biopharmaceutical company’s stock after buying an additional 31,055 shares during the period. Sei Investments Co.’s holdings in Royalty Pharma were worth $1,821,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in RPRX. Swedbank AB acquired a new stake in shares of Royalty Pharma during the first quarter worth about $251,461,000. New South Capital Management Inc. acquired a new stake in shares of Royalty Pharma during the first quarter worth about $44,384,000. ADAR1 Capital Management LLC acquired a new stake in shares of Royalty Pharma during the fourth quarter worth about $37,130,000. Patient Capital Management LLC acquired a new stake in shares of Royalty Pharma during the fourth quarter worth about $35,247,000. Finally, Homestead Advisers Corp raised its position in Royalty Pharma by 40.7% in the 1st quarter. Homestead Advisers Corp now owns 1,892,540 shares of the biopharmaceutical company’s stock valued at $57,502,000 after buying an additional 547,000 shares during the last quarter. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Price Performance

NASDAQ:RPRX opened at $27.75 on Friday. The firm has a market capitalization of $16.47 billion, a price-to-earnings ratio of 20.71, a price-to-earnings-growth ratio of 4.17 and a beta of 0.46. Royalty Pharma plc has a twelve month low of $25.20 and a twelve month high of $31.66. The stock’s 50 day moving average price is $27.95 and its two-hundred day moving average price is $27.85. The company has a quick ratio of 9.35, a current ratio of 9.35 and a debt-to-equity ratio of 0.78.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.01. The firm had revenue of $537.00 million for the quarter, compared to analyst estimates of $600.83 million. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. During the same quarter in the previous year, the firm earned $0.85 EPS. Equities research analysts expect that Royalty Pharma plc will post 4.04 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 13th. Shareholders of record on Friday, August 16th were given a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a dividend yield of 3.03%. The ex-dividend date of this dividend was Friday, August 16th. Royalty Pharma’s dividend payout ratio (DPR) is 62.69%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on RPRX. Morgan Stanley lifted their target price on Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a research report on Thursday, July 11th. The Goldman Sachs Group lifted their target price on Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Finally, StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, September 17th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $42.00.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.